Oncternal Therapeutics, Inc. announced On May 26, 2023, Gunnar Kaufmann, Ph.D. notified Oncternal Therapeutics, Inc. (“ Oncternal”) that he would be resigning as Chief Scientific Officer effective June 14, 2023 to pursue other opportunities. Dr. Kaufmann and Oncternal have agreed to enter into a consulting agreement pursuant to which Dr. Kaufmann will assist Oncternal with transition matters. The equity awards held by Dr. Kaufmann as of June 14, 2023 will continue to vest during the term of the agreement.

Dr. Kaufmann may also be compensated at a market hourly rate.